

## **Anti Tuberculosis Therapeutics Market Report and Forecast 2024-2032**

Market Report (7 days) | 2024-02-01 | 180 pages | EMR Inc.

### **AVAILABLE LICENSES:**

- Single User License \$5499.00
- Five User License \$7499.00
- Corporate License \$9499.00

### **Report description:**

Anti Tuberculosis Therapeutics Market Report and Forecast 2024-2032

Anti Tuberculosis Therapeutics Market Outlook

The anti-tuberculosis therapeutics market size was valued at USD 1,354 million in 2023, driven by the rise of multidrug-resistant TB strains in the major markets. The market size is anticipated to grow at a CAGR of 7.6% during the forecast period of 2024-2032 to achieve a value of USD 2589.8 million by 2032.

Tuberculosis: Introduction

Tuberculosis (TB) therapeutics involve a regimen of antibiotics to effectively treat TB, a contagious bacterial infection caused by *Mycobacterium tuberculosis*. Treatment usually requires a long-term course of multiple antibiotics to ensure complete eradication of the bacteria and prevent resistance. Common drugs include isoniazid, rifampin, ethambutol, and pyrazinamide. Monitoring and adherence to the treatment plan are crucial for success, as improper use can lead to drug-resistant strains, making the disease harder to treat.

Key Trends in the Anti Tuberculosis Therapeutics Market

There is an ongoing effort to develop new and more effective drugs to combat TB, especially drug-resistant strains. The market is witnessing the introduction of novel drug candidates and combination therapies aimed at reducing treatment duration and improving patient outcomes.

With the rise of multidrug-resistant TB strains, there's an increased focus on developing treatments specifically targeting these strains. Pharmaceutical companies and research institutions are investing in the development of drugs that can effectively treat MDR-TB and extensively drug-resistant TB (XDR-TB).

Governments and international organizations are providing financial support for research and development in TB therapeutics. This includes funding for clinical trials to test new drugs and treatment regimens.

Collaborations between governments, non-profit organizations, and pharmaceutical companies are becoming more common to pool resources and expertise in the fight against TB. These partnerships aim to accelerate drug development and ensure access to treatment in low- and middle-income countries.

Healthcare providers are increasingly adopting patient-centered approaches to ensure adherence to TB treatment regimens. This includes the use of digital health tools for monitoring treatment progress and providing support to patients.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

International health initiatives, such as the Stop TB Partnership and the Global Fund, play a crucial role in combating TB. These initiatives support drug development, improve access to medicines, and fund programs for TB control and prevention, particularly in regions with high TB prevalence.

#### Anti Tuberculosis Therapeutics Market Segmentation

##### Market Breakup by Treatment Type

- First-Line of Drugs
- Second-Line of Drugs
- Others

##### Market Breakup by Disease Type

- Active TB
- Latent TB
- Others

##### Market Breakup by Diagnosis

- Blood Tests
- Imaging Tests
- Sputum Tests
- Others

##### Market Breakup by Route of Administration

- Oral
- Parenteral
- Others

##### Market Breakup by Dosage Form

- Tablets
- Capsules
- Injections
- Others

##### Market Breakup by End User

- Hospitals
- Specialty Clinics
- Others

##### Market Breakup by Region

- United States
- EU-4 and the United Kingdom
  - o□Germany
  - o□France
  - o□Italy
  - o□Spain
  - o□United Kingdom
- Japan

#### Anti Tuberculosis Therapeutics Market Overview

In North America, the anti-tuberculosis therapeutics market is well-established, with a strong emphasis on public health initiatives and advanced healthcare infrastructure. The region has effective TB control programs, ensuring early diagnosis and treatment adherence. There's also a significant focus on research and development of new therapies and drug-resistant TB solutions, supported by government funding and collaborations between healthcare institutions and pharmaceutical companies. Europe's market benefits from comprehensive healthcare systems and robust TB surveillance and treatment programs. The region is active in addressing drug-resistant TB through research and collaborative European health initiatives. Access to advanced

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

healthcare facilities and a focus on high-quality care contribute to effective TB management. Efforts are also directed towards integrating TB care with services for related conditions like HIV, enhancing overall treatment outcomes.

The market in the Japan region is diverse, efforts to control TB are challenged by factors such as population density, healthcare access, and economic disparities. However, increasing healthcare investment, government initiatives, and international support are enhancing TB diagnosis and treatment. The region also focuses on addressing drug-resistant TB and improving public health education and TB awareness.

#### Anti Tuberculosis Therapeutics Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.

- AstraZeneca
- Johnson & Johnson Private Limited
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Novartis
- Allergan
- Merck & Co.
- STI Pharma
- Endo International plc
- Fresenius Kabi AG
- Hikma Pharmaceuticals PLC

We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

#### Table of Contents:

- 1 Preface
  - 1.1 Objectives of the Study
  - 1.2 Key Assumptions
  - 1.3 Report Coverage - Key Segmentation and Scope
  - 1.4 Research Methodology
- 2 Executive Summary
- 3 Tuberculosis Overview
  - 3.1 Guidelines and Stages
  - 3.2 Pathophysiology
  - 3.3 Screening and Diagnosis
  - 3.4 Treatment Pathway
- 4 Patient Profile
  - 4.1 Patient Profile Overview
  - 4.2 Patient Psychology and Emotional Impact Factors
  - 4.3 Risk Assessment and Treatment Success Rate
- 5 Tuberculosis Epidemiology Analysis - Seven Major Markets
  - 5.1 7MM Epidemiology Scenario Overview (2017-2032)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 5.2 United States Tuberculosis Epidemiology Forecast (2017-2032)
- 5.3 EU-4 and United Kingdom Tuberculosis Epidemiology Forecast (2017-2032)
  - 5.3.1 Germany Tuberculosis Epidemiology Forecast (2017-2032)
  - 5.3.2 France Tuberculosis Epidemiology Forecast (2017-2032)
  - 5.3.3 Italy Tuberculosis Epidemiology Forecast (2017-2032)
  - 5.3.4 Spain Tuberculosis Epidemiology Forecast (2017-2032)
  - 5.3.5 United Kingdom Tuberculosis Epidemiology Forecast (2017-2032)
- 5.4 Japan Tuberculosis Epidemiology Forecast (2017-2032)
- 6 Anti Tuberculosis Therapeutics Market Overview - Seven Major Markets
  - 6.1 Anti Tuberculosis Therapeutics Market Historical Value (2017-2023)
  - 6.2 Anti Tuberculosis Therapeutics Market Forecast Value (2024-2032)
- 7 Anti Tuberculosis Therapeutics Market Landscape - Seven Major Markets
  - 7.1 Anti Tuberculosis Therapeutics: Developers Landscape
    - 7.1.1 Analysis by Year of Establishment
    - 7.1.2 Analysis by Company Size
    - 7.1.3 Analysis by Region
  - 7.2 Anti Tuberculosis Therapeutics Product Landscape
    - 7.2.1 Analysis by Treatment Type
    - 7.2.2 Analysis by Route of Administration
    - 7.2.3 Analysis by End User
- 8 Anti Tuberculosis Therapeutics Challenges and Unmet Needs
  - 8.1 Treatment Pathway Challenges
  - 8.2 Compliance and Drop-Out Analysis
  - 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Anti Tuberculosis Therapeutics Market Dynamics
  - 10.1 Market Drivers and Constraints
  - 10.2 SWOT Analysis
  - 10.3 Porter's Five Forces Model
  - 10.4 Key Demand Indicators
  - 10.5 Key Price Indicators
  - 10.6 Industry Events, Initiatives, and Trends
  - 10.7 Value Chain Analysis
- 11 Anti Tuberculosis Therapeutics Market Segmentation - Seven Major Markets
  - 11.1 Anti Tuberculosis Therapeutics Market by Treatment Type
    - 11.1.1 Market Overview
    - 11.1.2 First-Line of Drugs
    - 11.1.3 Second-Line of Drugs
    - 11.1.4 Others
  - 11.2 Anti Tuberculosis Therapeutics Market by Disease Type
    - 11.2.1 Market Overview
    - 11.2.2 Active TB
    - 11.2.3 Latent TB
    - 11.2.4 Others
  - 11.3 Anti Tuberculosis Therapeutics Market by Diagnosis
    - 11.3.1 Market Overview
    - 11.3.2 Blood Tests

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 11.3.3 Imaging Tests
- 11.3.4 Sputum Tests
- 11.3.5 Others
- 11.4 Anti Tuberculosis Therapeutics Market by Route of Administration
  - 11.4.1 Market Overview
  - 11.4.2 Oral
  - 11.4.3 Parenteral
  - 11.4.4 Others
- 11.5 Anti Tuberculosis Therapeutics Market by Dosage Form
  - 11.5.1 Market Overview
  - 11.5.2 Tablets
  - 11.5.3 Capsules
  - 11.5.4 Injections
  - 11.5.5 Others
- 11.6 Anti Tuberculosis Therapeutics Market by End User
  - 11.6.1 Market Overview
  - 11.6.2 Hospitals
  - 11.6.3 Speciality Clinics
  - 11.6.4 Others
- 11.7 Anti Tuberculosis Therapeutics Market by Region
  - 11.7.1 Market Overview
  - 11.7.2 United States
  - 11.7.3 EU-4 and the United Kingdom
    - 11.7.3.1 Germany
    - 11.7.3.2 France
    - 11.7.3.3 Italy
    - 11.7.3.4 Spain
    - 11.7.3.5 United Kingdom
  - 11.7.4 Japan
- 12 United States Anti Tuberculosis Therapeutics Market
  - 12.1 Anti Tuberculosis Therapeutics Market Historical Value (2017-2023)
  - 12.2 Anti Tuberculosis Therapeutics Market Forecast Value (2024-2032)
  - 12.3 Anti Tuberculosis Therapeutics Market by Disease Type
  - 12.4 Anti Tuberculosis Therapeutics Market by Treatment Type
- 13 EU-4 and United Kingdom Anti Tuberculosis Therapeutics Market
  - 13.1 Anti Tuberculosis Therapeutics Market Historical Value (2017-2023)
  - 13.2 Anti Tuberculosis Therapeutics Market Forecast Value (2024-2032)
  - 13.3 Germany Anti Tuberculosis Therapeutics Market Overview
    - 13.3.1 Anti Tuberculosis Therapeutics Market by Disease Type
    - 13.3.2 Anti Tuberculosis Therapeutics Market by Treatment Type
  - 13.4 France Anti Tuberculosis Therapeutics Market Overview
    - 13.4.1 Anti Tuberculosis Therapeutics Market by Disease Type
    - 13.4.2 Anti Tuberculosis Therapeutics Market by Treatment Type
  - 13.5 Italy Anti Tuberculosis Therapeutics Market Overview
    - 13.5.1 Anti Tuberculosis Therapeutics Market by Disease Type
    - 13.5.2 Anti Tuberculosis Therapeutics Market by Treatment Type
  - 13.6 Spain Anti Tuberculosis Therapeutics Market Overview

- 13.6.1 Anti Tuberculosis Therapeutics Market by Disease Type
- 13.6.2 Anti Tuberculosis Therapeutics Market by Treatment Type
- 13.7 United Kingdom Anti Tuberculosis Therapeutics Market Overview
  - 13.7.1 Anti Tuberculosis Therapeutics Market by Disease Type
  - 13.7.2 Anti Tuberculosis Therapeutics Market by Treatment Type
- 14 Japan Anti Tuberculosis Therapeutics Market
  - 14.1 Anti Tuberculosis Therapeutics Market Historical Value (2017-2023)
  - 14.2 Anti Tuberculosis Therapeutics Market Forecast Value (2024-2032)
  - 14.3 Anti Tuberculosis Therapeutics Market by Disease Type
  - 14.4 Anti Tuberculosis Therapeutics Market by Treatment Type
- 15 Regulatory Framework
  - 15.1 Regulatory Overview
    - 15.1.1 US FDA
    - 15.1.2 EU EMA
    - 15.1.3 JAPAN PMDA
- 16 Patent Analysis
  - 16.1 Analysis by Type of Patent
  - 16.2 Analysis by Publication year
  - 16.3 Analysis by Issuing Authority
  - 16.4 Analysis by Patent Age
  - 16.5 Analysis by CPC Analysis
  - 16.6 Analysis by Patent Valuation
  - 16.7 Analysis by Key Players
- 17 Grants Analysis
  - 17.1 Analysis by year
  - 17.2 Analysis by Amount Awarded
  - 17.3 Analysis by Issuing Authority
  - 17.4 Analysis by Grant Application
  - 17.5 Analysis by Funding Institute
  - 17.6 Analysis by NIH Departments
  - 17.7 Analysis by Recipient Organization
- 18 Clinical Trials Analysis
  - 18.1 Analysis by Trial Registration Year
  - 18.2 Analysis by Trial Status
  - 18.3 Analysis by Trial Phase
  - 18.4 Analysis by Therapeutic Area
  - 18.5 Analysis by Geography
- 19 Funding and Investment Analysis
  - 19.1 Analysis by Funding Instances
  - 19.2 Analysis by Type of Funding
  - 19.3 Analysis by Funding Amount
  - 19.4 Analysis by Leading Players
  - 19.5 Analysis by Leading Investors
  - 19.6 Analysis by Geography
- 20 Partnerships and Collaborations Analysis
  - 20.1 Analysis by Partnership Instances
  - 20.2 Analysis by Type of Partnership

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 20.3 Analysis by Leading Players
- 20.4 Analysis by Geography
- 21 Supplier Landscape
  - 21.1 AstraZeneca
    - 21.1.1 Financial Analysis
    - 21.1.2 Product Portfolio
    - 21.1.3 Demographic Reach and Achievements
    - 21.1.4 Mergers and Acquisitions
    - 21.1.5 Certifications
  - 21.2 Johnson & Johnson Private Limited
    - 21.2.1 Financial Analysis
    - 21.2.2 Product Portfolio
    - 21.2.3 Demographic Reach and Achievements
    - 21.2.4 Mergers and Acquisitions
    - 21.2.5 Certifications
  - 21.3 Eli Lilly and Company
    - 21.3.1 Financial Analysis
    - 21.3.2 Product Portfolio
    - 21.3.3 Demographic Reach and Achievements
    - 21.3.4 Mergers and Acquisitions
    - 21.3.5 Certifications
  - 21.4 F. Hoffmann-La Roche Ltd.
    - 21.4.1 Financial Analysis
    - 21.4.2 Product Portfolio
    - 21.4.3 Demographic Reach and Achievements
    - 21.4.4 Mergers and Acquisitions
    - 21.4.5 Certifications
  - 21.5 Mylan N.V.
    - 21.5.1 Financial Analysis
    - 21.5.2 Product Portfolio
    - 21.5.3 Demographic Reach and Achievements
    - 21.5.4 Mergers and Acquisitions
    - 21.5.5 Certifications
  - 21.6 Teva Pharmaceutical Industries Ltd.
    - 21.6.1 Financial Analysis
    - 21.6.2 Product Portfolio
    - 21.6.3 Demographic Reach and Achievements
    - 21.6.4 Mergers and Acquisitions
    - 21.6.5 Certifications
  - 21.7 Sanofi
    - 21.7.1 Financial Analysis
    - 21.7.2 Product Portfolio
    - 21.7.3 Demographic Reach and Achievements
    - 21.7.4 Mergers and Acquisitions
    - 21.7.5 Certifications
  - 21.8 Novartis
    - 21.8.1 Financial Analysis

- 21.8.2 Product Portfolio
- 21.8.3 Demographic Reach and Achievements
- 21.8.4 Mergers and Acquisitions
- 21.8.5 Certifications
- 21.9 Allergan
  - 21.9.1 Financial Analysis
  - 21.9.2 Product Portfolio
  - 21.9.3 Demographic Reach and Achievements
  - 21.9.4 Mergers and Acquisitions
  - 21.9.5 Certifications
- 21.10 Merck & Co.
  - 21.10.1 Financial Analysis
  - 21.10.2 Product Portfolio
  - 21.10.3 Demographic Reach and Achievements
  - 21.10.4 Mergers and Acquisitions
  - 21.10.5 Certifications
- 21.11 STI Pharma
  - 21.11.1 Financial Analysis
  - 21.11.2 Product Portfolio
  - 21.11.3 Demographic Reach and Achievements
  - 21.11.4 Mergers and Acquisitions
  - 21.11.5 Certifications
- 21.12 Endo International plc
  - 21.12.1 Financial Analysis
  - 21.12.2 Product Portfolio
  - 21.12.3 Demographic Reach and Achievements
  - 21.12.4 Mergers and Acquisitions
  - 21.12.5 Certifications
- 21.13 Fresenius Kabi AG
  - 21.13.1 Financial Analysis
  - 21.13.2 Product Portfolio
  - 21.13.3 Demographic Reach and Achievements
  - 21.13.4 Mergers and Acquisitions
  - 21.13.5 Certifications
- 21.14 Hikma Pharmaceuticals PLC
  - 21.14.1 Financial Analysis
  - 21.14.2 Product Portfolio
  - 21.14.3 Demographic Reach and Achievements
  - 21.14.4 Mergers and Acquisitions
  - 21.14.5 Certifications
- 22 Anti Tuberculosis Therapeutics Market- Distribution Model (Additional Insight)
  - 22.1 Overview
  - 22.2 Potential Distributors
  - 22.3 Key Parameters for Distribution Partner Assessment
- 23 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 24 Company Competitiveness Analysis (Additional Insight)
  - 24.1 Very Small Companies

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)



- 24.2 Small Companies
- 24.3 Mid-Sized Companies
- 24.4 Large Companies
- 24.5 Very Large Companies
- 25 Payment Methods (Additional Insight)
  - 25.1 Government Funded
  - 25.2 Private Insurance
  - 25.3 Out-of-Pocket

\*Additional insights provided are customisable as per client requirements.

## Anti Tuberculosis Therapeutics Market Report and Forecast 2024-2032

Market Report (7 days) | 2024-02-01 | 180 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

### ORDER FORM:

Select license	License	Price
	Single User License	\$5499.00
	Five User License	\$7499.00
	Corporate License	\$9499.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ \*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-09"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com